MX2013006644A - Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina. - Google Patents

Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.

Info

Publication number
MX2013006644A
MX2013006644A MX2013006644A MX2013006644A MX2013006644A MX 2013006644 A MX2013006644 A MX 2013006644A MX 2013006644 A MX2013006644 A MX 2013006644A MX 2013006644 A MX2013006644 A MX 2013006644A MX 2013006644 A MX2013006644 A MX 2013006644A
Authority
MX
Mexico
Prior art keywords
nsaid
cyclodextrin
pharmaceutical formulation
novel pharmaceutical
novel
Prior art date
Application number
MX2013006644A
Other languages
English (en)
Other versions
MX343035B (es
Inventor
Alden Rodwell
Edward Beech
Mark Squires
Original Assignee
Reckitt Benckiser Healthcare Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare Int Ltd filed Critical Reckitt Benckiser Healthcare Int Ltd
Publication of MX2013006644A publication Critical patent/MX2013006644A/es
Publication of MX343035B publication Critical patent/MX343035B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una composición líquida que comprende una solución acuosa de un NSAID y una o más ciclodextrinas.
MX2013006644A 2010-12-15 2011-12-12 Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina. MX343035B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021267.8A GB201021267D0 (en) 2010-12-15 2010-12-15 Novel pharmaceutical formulation
PCT/GB2011/052457 WO2012080718A1 (en) 2010-12-15 2011-12-12 Novel pharmaceutical formulation comprising nsaid and cyclodextrin

Publications (2)

Publication Number Publication Date
MX2013006644A true MX2013006644A (es) 2013-08-09
MX343035B MX343035B (es) 2016-10-21

Family

ID=43567237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006644A MX343035B (es) 2010-12-15 2011-12-12 Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.

Country Status (14)

Country Link
US (2) US9138482B2 (es)
EP (1) EP2651409B1 (es)
KR (2) KR102013718B1 (es)
CN (1) CN103260617B (es)
AU (1) AU2011343030B2 (es)
BR (1) BR112013014833B1 (es)
ES (1) ES2602128T3 (es)
GB (2) GB201021267D0 (es)
MX (1) MX343035B (es)
PL (1) PL2651409T3 (es)
RU (1) RU2607592C2 (es)
TW (1) TWI526205B (es)
WO (1) WO2012080718A1 (es)
ZA (1) ZA201303261B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
JP2017527567A (ja) * 2014-09-17 2017-09-21 エピザイム インコーポレイテッド 癌の治療のための注射製剤
KR102545748B1 (ko) * 2017-12-26 2023-06-21 한미약품 주식회사 플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
CN111494307A (zh) * 2019-01-30 2020-08-07 北京普德康利医药科技发展有限公司 一种氟比洛芬注射液
GB2581344B (en) * 2019-02-11 2023-05-24 Reckitt Benckiser Health Ltd Novel composition
AU2020220560A1 (en) * 2019-02-11 2021-09-02 Reckitt Benckiser Health Limited Novel composition
CN110283259B (zh) * 2019-07-03 2021-12-10 宁夏医科大学 一种解热镇痛布洛芬-β-环糊精第一面衍生物及其制备方法
EP4121417A4 (en) * 2020-05-01 2023-08-09 University Of Southern California CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY
CN116870231A (zh) * 2023-08-03 2023-10-13 北京化工大学常州先进材料研究院 一种纳米纤维敷料

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5634618A (en) 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin
GB9316580D0 (en) 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
AU7637296A (en) * 1995-11-14 1997-06-05 Farmarc Nederland Bv Complex of naproxen and beta-cyclodextrin
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
AU8107998A (en) * 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO2004050123A2 (en) * 2002-11-27 2004-06-17 Pharmacia Corporation Concentrated liquid valdecoxib composition
CZ2004262A3 (cs) * 2004-02-20 2005-06-15 I. Q. A., A. S. Stabilní, chuťově přijatelné sirupy obsahující ibuprofen a způsob jejich přípravy
JP2007528384A (ja) * 2004-03-10 2007-10-11 シモダ、バイオテック（プロプライエタリー）リミテッド 安定な注射可能なジクロフェナク組成物
US20060120967A1 (en) * 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
EP1974751A1 (en) 2007-03-26 2008-10-01 The Jordanian Pharmaceutical Manufacturing Co. Formulations for non-steroidal anti-inflammatory drugs
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
CN101559077A (zh) * 2009-04-16 2009-10-21 官培龙 一种口腔炎症性疾病止痛用含漱液
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation

Also Published As

Publication number Publication date
RU2607592C2 (ru) 2017-01-10
ES2602128T3 (es) 2017-02-17
KR102013718B1 (ko) 2019-08-23
AU2011343030B2 (en) 2017-03-30
MX343035B (es) 2016-10-21
AU2011343030A1 (en) 2013-05-30
US9138482B2 (en) 2015-09-22
US10363316B2 (en) 2019-07-30
TWI526205B (zh) 2016-03-21
GB201121476D0 (en) 2012-01-25
US20160008478A1 (en) 2016-01-14
WO2012080718A1 (en) 2012-06-21
GB2486567A (en) 2012-06-20
GB2486567B (en) 2014-09-10
CN103260617A (zh) 2013-08-21
BR112013014833A2 (pt) 2018-05-15
ZA201303261B (en) 2014-07-30
GB201021267D0 (en) 2011-01-26
BR112013014833B1 (pt) 2022-09-20
RU2013132210A (ru) 2015-01-27
KR20130141555A (ko) 2013-12-26
KR20180110184A (ko) 2018-10-08
EP2651409B1 (en) 2016-08-10
EP2651409A1 (en) 2013-10-23
CN103260617B (zh) 2016-08-24
US20140296342A1 (en) 2014-10-02
PL2651409T3 (pl) 2017-05-31
TW201231048A (en) 2012-08-01

Similar Documents

Publication Publication Date Title
MX343035B (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
PH12014502860A1 (en) Racecadotril liquid compositions
MX344021B (es) Composiciones fluidas que comprenden un agente de estructuración.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
MX347795B (es) Formulaciones liquidas de st-246 y metodos.
EP3083925A4 (en) Stable liquid compositions containing enzymes and peroxides
AU332735S (en) Packaging container
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
MX339196B (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
CY1113065T1 (el) Συνθεσεις flupentixol
AU323419S (en) Teething device
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
PH12015502061A1 (en) Racecadotril liquid compositions
MY165088A (en) Pharmaceutical compositions comprising alisporivir
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
AU334513S (en) Display package
AU330684S (en) Medical dispensing device
IN2014KN02981A (es)
GB201004677D0 (en) New salt
AU334932S (en) Dispenser
TH147135A (th) สูตรผสมทางเภสัชกรรมชนิดใหม่ซึ่งประกอบรวมด้วย nsaid และไซโคลเด็กซ์ทริน
IN2014DN00168A (es)
AU347540S (en) External display device for toothbrush

Legal Events

Date Code Title Description
FG Grant or registration